Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2025 Ended September 30, 2024 and Provides Conference Call Information
Elite Pharmaceuticals (OTCQB: ELTP) reported strong financial results for Q2 FY2025 ended September 30, 2024. Consolidated revenues reached $18.9 million, marking a significant 33% increase ($4.7 million) compared to the same period last year. Operating profits rose to $3.5 million, showing an impressive 84% growth ($1.6 million) year-over-year. The improved performance was primarily driven by higher sales in Elite's label product line during the quarter.
Elite Pharmaceuticals (OTCQB: ELTP) ha riportato risultati finanziari solidi per il secondo trimestre dell'anno fiscale 2025, conclusosi il 30 settembre 2024. I ricavi consolidati hanno raggiunto 18,9 milioni di dollari, segnando un aumento significativo del 33% (4,7 milioni di dollari) rispetto allo stesso periodo dell'anno scorso. I profitti operativi sono aumentati a 3,5 milioni di dollari, mostrando una crescita impressionante dell'84% (1,6 milioni di dollari) anno su anno. La performance migliorata è stata principalmente guidata da un aumento delle vendite della linea di prodotti a marchio Elite durante il trimestre.
Elite Pharmaceuticals (OTCQB: ELTP) reportó resultados financieros sólidos para el segundo trimestre del año fiscal 2025, que finalizó el 30 de septiembre de 2024. Los ingresos consolidados alcanzaron los 18,9 millones de dólares, marcando un aumento significativo del 33% (4,7 millones de dólares) en comparación con el mismo período del año pasado. Los beneficios operativos aumentaron a 3,5 millones de dólares, mostrando un impresionante crecimiento del 84% (1,6 millones de dólares) interanual. El rendimiento mejorado fue impulsado principalmente por un aumento en las ventas de la línea de productos de marca Elite durante el trimestre.
엘리트 제약 (OTCQB: ELTP)은 2024년 9월 30일로 종료된 2025 회계연도 2분기에 대한 강력한 재무 결과를 발표했습니다. 통합 수익은 1,890만 달러에 달하여, 지난해 같은 기간에 비해 33% (470만 달러) 증가했습니다. 영업 이익은 350만 달러로 증가하였으며, 전년 대비 84% (160만 달러)의 인상적인 성장을 보였습니다. 개선된 성과는 주로 분기 동안 엘리트의 브랜드 제품 라인에서의 높은 판매에 의해 주도되었습니다.
Elite Pharmaceuticals (OTCQB: ELTP) a annoncé de solides résultats financiers pour le deuxième trimestre de l'exercice 2025, s'étant terminé le 30 septembre 2024. Les revenus consolidés ont atteint 18,9 millions de dollars, marquant une augmentation significative de 33% (4,7 millions de dollars) par rapport à la même période de l'année dernière. Les bénéfices d'exploitation ont augmenté à 3,5 millions de dollars, affichant une croissance impressionnante de 84% (1,6 million de dollars) par rapport à l'année précédente. La performance améliorée a été principalement due à des ventes plus élevées dans la ligne de produits de marque Elite au cours du trimestre.
Elite Pharmaceuticals (OTCQB: ELTP) hat starke Finanzzahlen für das 2. Quartal des Geschäftsjahres 2025, das am 30. September 2024 endete, veröffentlicht. Die konsolidierten Einnahmen erreichten 18,9 Millionen Dollar, was einem signifikanten Anstieg von 33% (4,7 Millionen Dollar) im Vergleich zum gleichen Zeitraum des Vorjahres entspricht. Die Betriebsgewinne stiegen auf 3,5 Millionen Dollar, was einem beeindruckenden Wachstum von 84% (1,6 Millionen Dollar) im Jahresvergleich entspricht. Die verbesserte Leistung wurde hauptsächlich durch höhere Verkäufe in der Produktlinie von Elite während des Quartals angetrieben.
- Revenue increased 33% year-over-year to $18.9 million
- Operating profits grew 84% to $3.5 million
- Strong performance in Elite label product line
- None.
Conference Call Scheduled for Friday, November 15 at 11:30 AM EST
Northvale, New Jersey--(Newsfile Corp. - November 14, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company engaged in the development, manufacture, and distribution of niche generic products, announced results for the three months ended September 30, 2024, which is the second quarter of the Company's fiscal year ending on March 31, 2025 ("Second Quarter").
Consolidated revenues for the three months ended September 30, 2024, were
Conference Call Information
Elite's management will host a conference call to discuss the Second Quarter financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
Date: | September 15, 2024 |
Time: | 11:30 AM EST |
Dial-in numbers: | 1-800-346-7359 (domestic) |
Conference number: | 98840 |
Questions: | dianne@elitepharma.com |
Audio Replay: |
The financial statements can be viewed for Elite's Second Quarter of Fiscal Year 2025 on Form 10-Q here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing and manufacturing oral, controlled-release drug products. Elite owns multiple generic products, some of which are licensed to Prasco, LLC and TAGI Pharma. Elite operates a cGMP and DEA-registered facility for research, development, and manufacturing located in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite's filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/229976
FAQ
What was Elite Pharmaceuticals (ELTP) revenue in Q2 2025?
How much did Elite Pharmaceuticals (ELTP) operating profits increase in Q2 2025?
What drove Elite Pharmaceuticals (ELTP) growth in Q2 2025?
